Analyst Price Targets — REGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 2, 2026 1:46 pm | Brian Abrahams | RBC Capital | $765.00 | $784.06 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital |
| February 9, 2026 11:47 am | — | Guggenheim | $975.00 | $785.51 | TheFly | Regeneron price target raised to $975 from $865 at Guggenheim |
| February 2, 2026 1:02 pm | Carter Gould | Cantor Fitzgerald | $800.00 | $757.59 | TheFly | Regeneron price target raised to $800 from $740 at Cantor Fitzgerald |
| February 2, 2026 12:51 pm | Brian Skorney | Robert W. Baird | $742.00 | $755.34 | TheFly | Regeneron price target raised to $742 from $630 at Baird |
| February 2, 2026 12:32 pm | — | Oppenheimer | $865.00 | $741.45 | TheFly | Regeneron price target raised to $865 from $750 at Oppenheimer |
| February 2, 2026 12:01 pm | William Pickering | Tudor Pickering | $925.00 | $753.13 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $925 at Bernstein SocGen Group |
| February 1, 2026 3:16 pm | Terence Flynn | Morgan Stanley | $769.00 | $741.45 | TheFly | Regeneron price target raised to $769 from $768 at Morgan Stanley |
| January 30, 2026 8:32 pm | — | Raymond James | $870.00 | $741.45 | TheFly | Regeneron price target raised to $870 from $820 at Raymond James |
| January 27, 2026 2:00 pm | William Pickering | Tudor Pickering | $916.00 | $762.10 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $916 at Bernstein |
| January 27, 2026 12:12 pm | Brian Abrahams | RBC Capital | $745.00 | $769.05 | StreetInsider | RBC Capital Reiterates Sector Perform Rating on Regeneron Pharma (REGN) |
Latest News for REGN
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
Compound Planning Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 990 shares of the biopharmaceutical company's stock, valued at approximately $557,000. Other large investors have also added to or reduced their stakes
The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than…
Regeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.25 billion.
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.